WHO Expert Committee on Biological Standardization
- PMID: 15693660
WHO Expert Committee on Biological Standardization
Abstract
This report presents the recommendations of a WHO Expert Committee commissioned to coordinate activities leading to the adoption of international requirements for the production and control of vaccines and other biologicals and the establishment of international biological reference materials. The report starts with a discussion of general issues brought to the Committee's attention and provides information on the status and development of reference materials for various antibodies, antigens, blood products and related substances, cytokines, growth factors, and endocrinological substances. The second part of the report, of particular relevance to manufacturers and national regulatory authorities, contains recommendations for the production and quality control of meningococcal group C conjugate vaccines, guidelines for regulatory expectations for clinical evaluation of vaccines, guidelines for the production and quality control of inactivated oral cholera vaccines and guidelines on viral inactivation and removal procedures intended to assure the viral safety of human blood plasma products.
Similar articles
-
Who Expert Committee on Biological Standardization.World Health Organ Tech Rep Ser. 2004;926:1-109. World Health Organ Tech Rep Ser. 2004. PMID: 15918537
-
WHO Expert Committee on biological standardization.World Health Organ Tech Rep Ser. 2007;(941):1-340, back cover. World Health Organ Tech Rep Ser. 2007. PMID: 18314862
-
WHO Expert Committee on Biological Standardization.World Health Organ Tech Rep Ser. 2002;904:i-vi, 1-107. World Health Organ Tech Rep Ser. 2002. PMID: 11980231
-
Scientific challenges for the quality control and production of group C meningococcal conjugate vaccines.Vaccine. 2004 Feb 25;22(8):1047-53. doi: 10.1016/j.vaccine.2003.08.040. Vaccine. 2004. PMID: 15161082 Review.
-
Evaluation of cell substrates for the production of biologicals: Revision of WHO recommendations. Report of the WHO Study Group on Cell Substrates for the Production of Biologicals, 22-23 April 2009, Bethesda, USA.Biologicals. 2010 Jan;38(1):162-9. doi: 10.1016/j.biologicals.2009.08.019. Epub 2009 Oct 8. Biologicals. 2010. PMID: 19818645 Review.
Cited by
-
Effect of CYP2C9, VKORC1, CYP4F2 and GGCX genetic variants on warfarin maintenance dose and explicating a new pharmacogenetic algorithm in South Indian population.Eur J Clin Pharmacol. 2014 Jan;70(1):47-56. doi: 10.1007/s00228-013-1581-x. Epub 2013 Sep 10. Eur J Clin Pharmacol. 2014. PMID: 24019055
-
TnBP⁄Triton X-45 treatment of plasma for transfusion efficiently inactivates hepatitis C virus.PLoS One. 2015 Feb 6;10(2):e0117800. doi: 10.1371/journal.pone.0117800. eCollection 2015. PLoS One. 2015. PMID: 25658612 Free PMC article.
-
Effectiveness of HPV vaccine by age at vaccination and number of doses: protocol for a population-based matched case-control study.BMJ Open. 2021 Apr 19;11(4):e043093. doi: 10.1136/bmjopen-2020-043093. BMJ Open. 2021. PMID: 33875441 Free PMC article.
-
Protective meningococcal capsular polysaccharide epitopes and the role of O acetylation.Clin Vaccine Immunol. 2007 May;14(5):577-84. doi: 10.1128/CVI.00009-07. Epub 2007 Mar 21. Clin Vaccine Immunol. 2007. PMID: 17376859 Free PMC article. Clinical Trial.
-
Estimation of plasma levels of warfarin and 7-hydroxy warfarin by high performance liquid chromatography in patients receiving warfarin therapy.J Young Pharm. 2013 Mar;5(1):13-7. doi: 10.1016/j.jyp.2013.02.001. Epub 2013 Mar 16. J Young Pharm. 2013. PMID: 24023446 Free PMC article.